SCHEMBL26318531

SCHEMBL26318531

O=C1NC(O)CCC1N1Cc2ccc(O)cc2C1=O

nearest known ligand 0.66

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CRBN Q96SW2 19/20 0.66
MAP1LC3B Q9GZQ8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24817721 0.90 CRBN (0.66) CRBNMAP1LC3B
SCHEMBL25123189 0.86 CRBN (0.65) CRBN
SCHEMBL24592273 0.83 CRBN (0.61) CRBN
SCHEMBL24920904 0.83 CRBN (0.61) CRBN
SCHEMBL29439976 0.80 CRBN (1.00) CRBNMAP1LC3B
SCHEMBL21760366 0.80 CRBN (1.00) CRBNMAP1LC3B
SCHEMBL24046600 0.79 CRBN (0.65) CRBN
SCHEMBL19022946 0.76 CRBN (0.60) CRBN
SCHEMBL27339978 0.76 CRBN (0.46) CRBN
SCHEMBL23138822 0.76 CRBN (0.46) CRBN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE CULLGEN (SHANGHAI), INC. (CN) 2023-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257380-A1 TROPOMYOSIN RECEPTOR KINASE (TRK) DEGRADATION COMPOUNDS AND METHODS OF USE MUSK, ERBB2, NTRK1 CRBN 330/4885MAP1LC3B 811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.